Tamoxifen: the drug that came in from the cold

Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes-Davies, L, Caldas, C, Wishart, G C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743359/
https://www.ncbi.nlm.nih.gov/pubmed/19672259
http://dx.doi.org/10.1038/sj.bjc.6605231
Descripción
Sumario:Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.

Ejemplares similares